The story of Sildenafil presents a nuanced case for observers in the medicinal sector. While initially a blockbuster success, generating vast sums, the exclusivity end and the subsequent entry of generic alternatives have considerably changed earnings. This raises questions about the future profitability of related therapeutic innovations and su… Read More